June 2025 in “Pharmaceuticals” Finasteride use may increase suicidality risk, especially in young men.
March 2025 in “International Journal of Dermatology” Baricitinib may help people with long-term alopecia areata.
August 2024 in “Journal of Clinical Medicine” Systemic treatments like hydroxychloroquine and cyclosporine A help with Lichen Planopilaris and Frontal Fibrosing Alopecia, but ongoing treatment is needed.
June 2024 in “Journal of Clinical Oncology” The combination of TACE and Donafenib is effective and tolerable for treating unresectable liver cancer.
March 2024 in “Indian Journal of Dermatology” Iron supplements may improve hair loss satisfaction even if initial iron levels are normal.
December 2023 in “Acta dermato-venereologica” Tofacitinib is effective for treating alopecia areata, and starting treatment early may improve results.
December 2023 in “Dermatology and therapy” Japanese patients and physicians often disagree on the severity of Alopecia Areata and treatment satisfaction, needing better communication and treatments.
June 2023 in “British Journal of Dermatology” Baricitinib was effective and safe for severe hair loss treatment over 6 months.
December 2022 in “International Journal of Research in Dermatology” Growth factor concentrate therapy helps manage hair loss.
Antifungal treatment reduced asthma exacerbations and corticosteroid use but its overall benefit is unclear.
May 2015 in “Cancer research” After chemotherapy for early breast cancer, 33.4% of patients had long-term significant hair loss, with some hair regrowth over time, but treatments for hair loss were largely ineffective.
70 citations
,
February 2018 in “Seminars in Arthritis and Rheumatism” Belimumab reduces disease activity, steroid use, and flares in lupus patients.
21 citations
,
October 1978 in “The Journal of Clinical Pharmacology” 22 citations
,
February 2023 in “European Journal of Neurology” Fremanezumab effectively reduces migraines and improves quality of life with mild side effects.
8 citations
,
February 2007 in “Journal of The American Academy of Dermatology” Higher serum ferritin levels than currently used might be needed to rule out iron deficiency in women with hair loss.
4 citations
,
May 2023 in “Composites Part B: Engineering” The nanocomposite hydrogels can repair themselves, change shape, reduce inflammation, protect against oxidation, kill bacteria, stop bleeding, and help heal diabetic wounds while allowing for wound monitoring.
2 citations
,
September 2024 in “Journal of the American Academy of Dermatology” Higher monocyte counts may predict poor response to adalimumab in hidradenitis suppurativa patients.
1 citations
,
September 2025 in “Eye” Certain drugs can cause eyelid inflammation, so doctors should monitor and educate patients on eyelid care.
1 citations
,
June 2023 in “Advances in therapy” Ripretinib is effective and safe for treating advanced GIST in Chinese patients, particularly for non-gastric GISTs.
These medications for BPH have known risks and may have new side effects.
These medications for BPH have known risks and may have new side effects.
January 2026 in “EJC Skin Cancer” The serum effectively improves hair growth and is well-tolerated for post-cancer hair loss.
December 2025 in “JMIR Dermatology” Topical finasteride is well-tolerated and satisfies most users with minimal side effects.
The combination of oral minoxidil, oral dutasteride, and mesotherapy is the most effective and safe for hair growth in AGA.
Most patients were satisfied with topical finasteride, and few experienced side effects.
Patients with acute and subacute skin lupus respond faster to belimumab than those with chronic skin lupus.
February 2024 in “medRxiv (Cold Spring Harbor Laboratory)” The study aims to understand how mood, physical activity, light exposure, and seasonal changes affect sleep patterns.
February 2021 in “Research Square (Research Square)” The Li-Pa/Ca and Do/Ca chemotherapy regimens for serous ovarian cancer showed better short-term and long-term results than the Pa/Ca regimen.
January 2021 in “Journal of clinical & experimental dermatology research” The new 5% minoxidil formulation without propylene glycol effectively promotes hair growth with fewer side effects and better user satisfaction.
January 2021 in “Medical research archives” The 5% minoxidil lotion without propylene glycol is effective, well-tolerated, and cosmetically acceptable for hair loss.